ImmunityBio Says Steps Taken to Address FDA Concerns Over Anktiva Podcast, TV Ad

MT Newswires Live

04/06

ImmunityBio (IBRX) said Monday that it has removed a podcast about its bladder cancer drug Anktiva from its website and asked third-party hosting platforms to remove the podcast to address the US Food and Drug Administration's concerns.

The company also said the television ad questioned by the regulator never aired.

In addition, ImmunityBio said it is executing other measures to improve advertising compliance, including expanded promotional review protocols and mandatory executive training.

In March, the FDA issued a warning letter to the company citing "false or misleading" promotional materials for Anktiva.

Anktiva, or nogapendekin alfa inbakicept-pmln), is indicated in combination with Bacillus Calmette-Guerin for the treatment of adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, the regulator said.

Shares of ImmunityBio were up 1.2% pre-bell Monday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2625679011"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625679011\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625679011?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-06 20:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625679011","market":"fut","top_or_hot":-1,"title":"ImmunityBio Says Steps Taken to Address FDA Concerns Over Anktiva Podcast, TV Ad","media":"MT Newswires Live","content":"<html><body><p> ImmunityBio (IBRX) said Monday that it has removed a podcast about its bladder cancer drug Anktiva from its website and asked third-party hosting platforms to remove the podcast to address the US Food and Drug Administration's concerns.</p><p>The company also said the television ad questioned by the regulator never aired.</p><p>In addition, ImmunityBio said it is executing other measures to improve advertising compliance, including expanded promotional review protocols and mandatory executive training.</p><p>In March, the FDA issued a warning letter to the company citing \"false or misleading\" promotional materials for Anktiva.</p><p>Anktiva, or nogapendekin alfa inbakicept-pmln), is indicated in combination with Bacillus Calmette-Guerin for the treatment of adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, the regulator said.</p><p>Shares of ImmunityBio were up 1.2% pre-bell Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Says Steps Taken to Address FDA Concerns Over Anktiva Podcast, TV Ad</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Says Steps Taken to Address FDA Concerns Over Anktiva Podcast, TV Ad\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-06 20:27</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> ImmunityBio (IBRX) said Monday that it has removed a podcast about its bladder cancer drug Anktiva from its website and asked third-party hosting platforms to remove the podcast to address the US Food and Drug Administration's concerns.</p><p>The company also said the television ad questioned by the regulator never aired.</p><p>In addition, ImmunityBio said it is executing other measures to improve advertising compliance, including expanded promotional review protocols and mandatory executive training.</p><p>In March, the FDA issued a warning letter to the company citing \"false or misleading\" promotional materials for Anktiva.</p><p>Anktiva, or nogapendekin alfa inbakicept-pmln), is indicated in combination with Bacillus Calmette-Guerin for the treatment of adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, the regulator said.</p><p>Shares of ImmunityBio were up 1.2% pre-bell Monday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TV","symbol_name":"墨西哥電視","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625679011","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625679011","pubTimestamp":1775478467,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ImmunityBio  said Monday that it has removed a podcast about its bladder cancer drug Anktiva from its website and asked third-party hosting platforms to remove the podcast to address the US Food and Drug Administration's concerns.The company also said the television ad questioned by the regulator never aired.In addition, ImmunityBio said it is executing other measures to improve advertising compliance, including expanded promotional review protocols and mandatory executive training.In March, the FDA issued a warning letter to the company citing \"false or misleading\" promotional materials for Anktiva.Anktiva, or nogapendekin alfa inbakicept-pmln), is indicated in combination with Bacillus Calmette-Guerin for the treatment of adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, the regulator said.Shares of ImmunityBio were up 1.2% pre-bell Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TV":"墨西哥电视","LABU":"三倍做多标普生物-Direxion"},"translate_title":"ImmunityBio表示已采取措施解决FDA对Anktiva播客和电视广告的担忧","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"TV":1.5},"content_text":"ImmunityBio (IBRX) said Monday that it has removed a podcast about its bladder cancer drug Anktiva from its website and asked third-party hosting platforms to remove the podcast to address the US Food and Drug Administration's concerns.The company also said the television ad questioned by the regulator never aired.In addition, ImmunityBio said it is executing other measures to improve advertising compliance, including expanded promotional review protocols and mandatory executive training.In March, the FDA issued a warning letter to the company citing \"false or misleading\" promotional materials for Anktiva.Anktiva, or nogapendekin alfa inbakicept-pmln), is indicated in combination with Bacillus Calmette-Guerin for the treatment of adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, the regulator said.Shares of ImmunityBio were up 1.2% pre-bell Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}